Download PDF
Semin Thromb Hemost 2002; 28(1): 53-66
DOI: 10.1055/s-2002-20564
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Heparin Inhibition of Selectin-Mediated Interactions during the Hematogenous Phase of Carcinoma Metastasis: Rationale for Clinical Studies in Humans

Nissi M. Varki, Ajit Varki
  • Departments of Medicine, Pathology, and Cellular and Molecular Medicine, Cancer Center and Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California
Further Information

Publication History

Publication Date:
05 March 2002 (online)

    Permissions and Reprints

ABSTRACT

Classic studies indicate that the formation of tumor cell-platelet complexes in the blood stream is important in facilitating the metastatic process. Metastasis in animal models can be inhibited by heparin, and retrospective analyses of heparin use in human cancer have shown promise. However, most follow-up human studies using vitamin K antagonists have failed, and conclusive proof for other previously proposed mechanisms of heparin action is lacking. Carcinoma progression and metastasis are associated with overexpression of sialylated fucosylated mucins. Structurally similar molecules happen to be natural ligands for vascular adhesion molecules called the selectins. Heparin also happens to be a good inhibitor of P-selectin, which is expressed on activated platelets or endothelial cells. We have found that heparin blocks P-selectin-mediated interactions of endogenous platelets with sialylated fucosylated mucins on circulating carcinoma cells and that this reduces tumor cell survival. The use of more specific and selective P-selectin inhibitors will some day help to dissect the relative importance of this mechanism of heparin action in cancer. Meanwhile, we suggest that the failure of vitamin K antagonists to improve cancer prognosis should be ignored and that heparin therapy should be immediately revisited under this new paradigm. Unlike the suggestions in most previous studies, we propose that heparin use should be reexplored specifically during the interval from initial visualization of a primary tumor until just after its definitive surgical removal. A suggested clinical trial is outlined.

KEYWORD

Carcinomas - mucins - platelets - P-selectin - heparin

REFERENCES

  • 1 Hart I R, Liotta L A. Developments in Oncology 7: Tumor Invasion and Metastasis.  The Hague: Martinus Nijhoff 1982
    Google Scholar
  • 2 Fidler I J. Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes Memorial Award lecture.  Cancer Res . 1990;  50 6130-6138
    PubMedGoogle Scholar
  • 3 Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction.  Cancer Metastasis Rev . 1990;  9 171-174
    CrossrefPubMedGoogle Scholar
  • 4 Kerbel R S. Significance of tumor-host interactions in cancer growth and metastases.  Cancer Metastasis Rev . 1995;  14 259-262
    CrossrefPubMedGoogle Scholar
  • 5 Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases.  Ann Intern Med . 1981;  95 636-641
    PubMedGoogle Scholar
  • 6 Gasic G J. Role of plasma, platelets, and endothelial cells in tumor metastasis.  Cancer Metastasis Rev . 1984;  3 99-114
    PubMedGoogle Scholar
  • 7 Honn K V, Tang D G, Crissman J D. Platelets and cancer metastasis: a causal relationship?.  Cancer Metastasis Rev . 1992;  11 325-351
    CrossrefPubMedGoogle Scholar
  • 8 Honn K V, Tang D G, Chen Y Q. Platelets and cancer metastasis: more than an epiphenomenon.  Semin Thromb Hemost . 1992;  18 392-415
    PubMedGoogle Scholar
  • 9 Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis.  Blood . 1984;  63 55-63
    PubMedGoogle Scholar
  • 10 Tanaka N G, Tohgo A, Ogawa H. Platelet-aggregating activities of metastasizing tumor cells. V. In situ roles of platelets in hematogenous metastases.  Invasion Metastasis . 1986;  6 209-224
    PubMedGoogle Scholar
  • 11 Tohgo A, Tanaka N G, Ogawa H. Platelet-aggregating activities of metastasizing tumor cells. IV. Effects of cell surface modification on thrombin generation, platelet aggregation and subsequent lung colonization.  Invasion Metastasis . 1986;  6 58-68
    PubMedGoogle Scholar
  • 12 Felding-Habermann B, Habermann R, Saldivar E, Ruggeri Z M. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow.  J Biol Chem . 1996;  271 5892-5900
    CrossrefPubMedGoogle Scholar
  • 13 Kato Y, Fujita N, Yano H, Tsuruo T. Suppression of experimental lung colonization of mouse colon adenocarcinoma 26 in vivo by an anti-idiotype monoclonal antibody recognizing a platelet surface molecule.  Cancer Res . 1997;  57 3040-3045
    PubMedGoogle Scholar
  • 14 Nieswandt B, Hafner M, Echtenacher B, Männel D N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets.  Cancer Res . 1999;  59 1295-1300
    PubMedGoogle Scholar
  • 15 Karpatkin S, Pearlstein E, Ambrogio C, Coller B S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo.  J Clin Invest . 1988;  81 1012-1019
    CrossrefPubMedGoogle Scholar
  • 16 Borsig L, Wong R, Feramisco J. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.  Proc Natl Acad Sci USA . 2001;  98 3352-3357
    CrossrefPubMedGoogle Scholar
  • 17 Zacharski L R, Ornstein D L. Heparin and cancer.  Thromb Haemost . 1998;  80 10-23
    PubMedGoogle Scholar
  • 18 Engelberg H. Actions of heparin that may affect the malignant process.  Cancer . 1999;  85 257-272
    CrossrefPubMedGoogle Scholar
  • 19 Hejna M, Raderer M, Zielinski C C. Inhibition of metastases by anticoagulants.  J Natl Cancer Inst . 1999;  91 22-36
    CrossrefPubMedGoogle Scholar
  • 20 Ornstein D L, Zacharski L R. The use of heparin for treating human malignancies.  Haemostasis . 1999;  29(Suppl 1) 48-60
    CrossrefPubMedGoogle Scholar
  • 21 Smorenburg S M, Hettiarachchi R JK, Vink R, Büller H R. The effects of unfractionated heparin on survival in patients with malignancy-a systematic review.  Thromb Haemost . 1999;  82 1600-1604
    PubMedGoogle Scholar
  • 22 Smorenburg S M, Van Noorden J F C. The complex effects of heparins on cancer progression and metastasis in experimental studies.  Pharmacol Rev . 2001;  53 93-105
    PubMedGoogle Scholar
  • 23 Fielding L P, Hittinger R, Grace R H, Fry J S. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma.  Lancet . 1992;  340 502-506
    CrossrefPubMedGoogle Scholar
  • 24 Lebeau B, Chastang C, Brechot J M. Subcutaneous heparin treatment increases survival in small cell lung cancer. ``Petites Cellules'' Group.  Cancer . 1994;  74 38-45
    CrossrefPubMedGoogle Scholar
  • 25 Kingston R D, Fielding J W, Palmer M K. Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer?.  Int J Colorectal Dis . 1993;  8 111-115
    CrossrefPubMedGoogle Scholar
  • 26 Kakkar A K, Hedges R A, Williamson R CN, Kakkar V V. Perioperative heparin therapy inhibits late death from metastatic cancer.  Int J Oncol . 1995;  6 885-888
    PubMedGoogle Scholar
  • 27 Nitti D, Wils J, Sahmoud T. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987).  Eur J Cancer [A] . 1997;  33A 1209-1215
    PubMedGoogle Scholar
  • 28 Hettiarachchi R JK, Smorenburg S M, Ginsberg J. Do heparins do more than just treat thrombosis?.  <~>The influence of heparins on cancer spread. Thromb Haemost . 1999;  82 947-952
    PubMedGoogle Scholar
  • 29 Kakkar A K, Williamson R CN. Antithrombotic therapy in cancer-low molecular weight heparins may have a direct effect on tumours.  Br Med J . 1999;  318 1571-1572
    PubMedGoogle Scholar
  • 30 Zacharski L R, Ornstein D L, Mamourian A C. Low-molecular-weight heparin and cancer.  Semin Thromb Hemost . 2000;  26(Suppl 1) 69-77
    Google Scholar
  • 31 Mueller B M, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.  J Clin Invest . 1998;  101 1372-1378
    Google Scholar
  • 32 Palumbo J S, Kombrinck K W, Drew A F. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.  Blood . 2000;  96 3302-3309
    Google Scholar
  • 33 Zacharski L R. Basis for selection of anticoagulant drugs for therapeutic trials in human malignancy.  Haemostasis . 1986;  16 300-320
    PubMedGoogle Scholar
  • 34 Zacharski L R, Henderson W G, Rickles F R. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75.  Cancer . 1984;  53 2046-2052
    CrossrefPubMedGoogle Scholar
  • 35 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.  N Engl J Med . 2000;  342 1953-1958
    CrossrefPubMedGoogle Scholar
  • 36 Taylor-Papadimitriou J, Burchell J, Miles D W, Dalziel M. MUC1 and cancer.  Biochim Biophys Acta Mol Basis Dis . 1999;  1455 301-313
    CrossrefPubMedGoogle Scholar
  • 37 Fukuda M. Possible roles of tumor-associated carbohydrate antigens.  Cancer Res . 1996;  56 2237-2244
    PubMedGoogle Scholar
  • 38 Kim Y J, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer.  Glycoconj J . 1997;  14 569-576
    CrossrefPubMedGoogle Scholar
  • 39 Hakomori S, Zhang Y. Glycosphingolipid antigens and cancer therapy.  Chem Biol . 1997;  4 97-104
    CrossrefPubMedGoogle Scholar
  • 40 Dennis J W, Granovsky M, Warren C E. Glycoprotein glycosylation and cancer progression.  Biochim Biophys Acta Gen Subj . 1999;  1473 21-34
    PubMedGoogle Scholar
  • 41 Kannagi R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer.  Glycoconj J . 1997;  14 577-584
    CrossrefPubMedGoogle Scholar
  • 42 Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism.  Cancer Res . 1996;  56 5309-5318
    PubMedGoogle Scholar
  • 43 Zhang K, Sikut R, Hansson G C. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells.  Cell Immunol . 1997;  176 158-165
    CrossrefPubMedGoogle Scholar
  • 44 Kim Y S, Gum J, Brockhausen I. Mucin glycoproteins in neoplasia.  Glycoconj J . 1996;  13 693-707
    CrossrefPubMedGoogle Scholar
  • 45 Matsushita Y, Yamamoto N, Shirahama H. Expression of sulfomucins in normal mucosae, colorectal adenocarcinomas, and metastases.  Jpn J Cancer Res . 1995;  86 1060-1067
    PubMedGoogle Scholar
  • 46 Bresalier R S, Niv Y, Byrd J C. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis.  J Clin Invest . 1991;  87 1037-1045
    PubMedGoogle Scholar
  • 47 Spicer A P, Rowse G J, Lidner T K, Gendler S J. Delayed mammary tumor progression in Muc-1 null mice.  J Biol Chem . 1995;  270 30093-30101
    CrossrefPubMedGoogle Scholar
  • 48 Sack G HJ, Levin J, Bell W R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features.  Medicine (Baltimore ) . 1977;  56 1-37
    PubMedGoogle Scholar
  • 49 Callander N, Rapaport S I. Trousseau's syndrome.  West J Med . 1993;  158 364-371
    PubMedGoogle Scholar
  • 50 Rickles F R, Levine M N. Venous thromboembolism in malignancy and malignancy in venous thromboembolism.  Haemostasis . 1998;  28(Suppl 3) 43-49
    CrossrefPubMedGoogle Scholar
  • 51 Prandoni P. Antithrombotic strategies in patients with cancer.  Thromb Haemost . 1997;  78 141-144
    PubMedGoogle Scholar
  • 52 Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseau's syndrome.  Cancer . 1997;  80 649-655
    CrossrefPubMedGoogle Scholar
  • 53 Levine M, Hirsh J, Gent M. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer.  Lancet . 1994;  343 886-889
    CrossrefPubMedGoogle Scholar
  • 54 Magnani J L, Brockhaus M, Smith D F, Ginsburg V. Detection of glycolipid ligands by direct binding of carbohydrate-binding proteins to thin-layer chromatograms.  Methods Enzymol . 1982;  83 235-241
    PubMedGoogle Scholar
  • 55 Fukushima K, Hirota M, Terasaki P I. Characterization of sialosylated Lewis X as a new tumor-associated antigen.  Cancer Res . 1984;  44 5279-5285
    PubMedGoogle Scholar
  • 56 Hoff S D, Matsushita Y, Ota D M. Increased expression of sialyl-dimeric Le antigen in liver metastases of human colorectal carcinoma.  Cancer Res . 1989;  49 6883-6888
    PubMedGoogle Scholar
  • 57 Iwanari O, Miyako J, Date Y. Clinical evaluations of the tumor marker sialyl SSEA-antigen for clinical gynecological disease.  Gynecol Obstet Invest . 1990;  29 214-218
    PubMedGoogle Scholar
  • 58 Matsushita Y, Cleary K R, Ota D M, Hoff S D, Irimura T. Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases.  Lab Invest . 1990;  63 780-791
    PubMedGoogle Scholar
  • 59 Matsusako T, Muramatsu H, Shirahama T, Muramatsu T, Ohi Y. Expression of a carbohydrate signal, sialyl dimeric LeX antigen, is associated with metastatic potential of transitional cell carcinoma of the human urinary bladder.  Biochem Biophys Res Commun . 1991;  181 1218-1222
    CrossrefPubMedGoogle Scholar
  • 60 Shirahama T, Ikoma M, Muramatsu H, Muramatsu T, Ohi Y. Reactivity to fucose-binding proteins of lotus tetragonolobus correlates with metastatic phenotype of transitional cell carcinoma of the bladder.  J Urol . 1992;  147 1659-1664
    PubMedGoogle Scholar
  • 61 Sinn H-P, Brown S A, Oberle E, Thompson J S. Analysis of the Lewisx epitope in human pancreas and pancreatic adenocarcinomas.  Int J Pancreatol . 1992;  11 125-135
    PubMedGoogle Scholar
  • 62 Nakamori S, Kameyama M, Imaoka S. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study.  Cancer Res . 1993;  53 3632-3637
    PubMedGoogle Scholar
  • 63 Nakayama T, Watanabe M, Katsumata T, Teramoto T, Kitajima M. Expression of sialyl Lewisa as a new prognostic factor for patients with advanced colorectal carcinoma.  Cancer . 1995;  75 2051-2056
    PubMedGoogle Scholar
  • 64 Ogawa J, Inoue H, Koide S. Expression of α-1,3-fucosyltransferase type IV and VII genes is related to poor prognosis in lung cancer.  Cancer Res . 1996;  56 325-329
    PubMedGoogle Scholar
  • 65 Idikio H A. Sialyl-Lewis-X.  Gleason grade and stage in non-metastatic human prostate cancer. Glycoconj J . 1997;  14 875-877
    PubMedGoogle Scholar
  • 66 Nakamori S, Kameyama M, Imaoka S. Involvement of carbohydrate antigen sialyl Lewisx in colorectal cancer metastasis.  Dis Colon Rectum . 1997;  40 420-431
    PubMedGoogle Scholar
  • 67 Weimbs T, Mostov K, Low S H, Hofmann R. A model for structural similarity between different SNARE complexes based on sequence relationships.  Trends Cell Biol . 1998;  8 260-262
    CrossrefPubMedGoogle Scholar
  • 68 Nakagoe T, Fukushima K, Nanashima A. Increased expression of sialyl Lex antigen in non-polypoid growth type of colorectal carcinoma.  Cancer Lett . 2000;  151 209-216
    CrossrefPubMedGoogle Scholar
  • 69 Benharroch D, Dima E, Levy A. Differential expression of sialyl and non-sialyl-CD15 antigens on Hodgkin-Reed-Sternberg cells: significance in Hodgkin's disease.  Leuk Lymphoma . 2000;  39 185-194
    PubMedGoogle Scholar
  • 70 Springer T A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.  Cell . 1994;  76 301-314
    CrossrefPubMedGoogle Scholar
  • 71 Kansas G S. Selectins and their ligands: current concepts and controversies.  Blood . 1996;  88 3259-3287
    PubMedGoogle Scholar
  • 72 McEver R P. Selectin-carbohydrate interactions during inflammation and metastasis.  Glycoconj J . 1997;  14 585-591
    CrossrefPubMedGoogle Scholar
  • 73 Varki A. Selectin ligands: will the real ones please stand up?.  J Clin Invest . 1997;  99 158-162
    PubMedGoogle Scholar
  • 74 McEver R P, Cummings R D. Role of PSGL-1 binding to selectins in leukocyte recruitment.  J Clin Invest . 1997;  100 485-492
    CrossrefPubMedGoogle Scholar
  • 75 Hemmerich S, Rosen S D. Carbohydrate sulfotransferases in lymphocyte homing.  Glycobiology . 2000;  10 849-856
    CrossrefPubMedGoogle Scholar
  • 76 Somers W S, Tang J, Shaw G D, Camphausen R T. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1.  Cell . 2000;  103 467-479
    CrossrefPubMedGoogle Scholar
  • 77 Stone J P, Wagner D D. P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer.  J Clin Invest . 1993;  92 804-813
    PubMedGoogle Scholar
  • 78 Mannori G, Crottet P, Cecconi O. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin type glycoproteins.  Cancer Res . 1995;  55 4425-4431
    PubMedGoogle Scholar
  • 79 Aigner S, Sthoeger Z M, Fogel M. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells.  Blood . 1997;  89 3385-3395
    PubMedGoogle Scholar
  • 80 Crottet P, Kim Y J, Varki A. Subsets of sialylated, sulfated mucins of diverse origins are recognized by L-selectin. Lack of evidence for unique oligosaccharide sequences mediating binding.  Glycobiology . 1996;  6 191-208
    PubMedGoogle Scholar
  • 81 Kim Y J, Borsig L, Han H L, Varki N M, Varki A. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium.  Am J Pathol . 1999;  155 461-472
    PubMedGoogle Scholar
  • 82 Kim Y J, Borsig L, Varki N M, Varki A. P-selectin deficiency attenuates tumor growth and metastasis.  Proc Natl Acad Sci USA . 1998;  95 9325-9330
    CrossrefPubMedGoogle Scholar
  • 83 Takada A, Ohmori K, Yoneda T. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium.  Cancer Res . 1993;  53 354-361
    PubMedGoogle Scholar
  • 84 Lorant D E, Topham M K, Whatley R E. Inflammatory roles of P-selectin.  J Clin Invest . 1993;  92 559-570
    PubMedGoogle Scholar
  • 85 Diacovo T G, Puri K D, Warnock R A, Springer T A, von Andrian H U. Platelet-mediated lymphocyte delivery to high endothelial venules.  Science . 1996;  273 252-255
    CrossrefPubMedGoogle Scholar
  • 86 McCarty O J, Mousa S A, Bray P F, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions.  Blood . 2000;  96 1789-1797
    PubMedGoogle Scholar
  • 87 Mellors A, Lo R YC. O-Sialoglycoprotease from Pasteurella haemolytica Methods Enzymol .  1995;  248 728-740
    PubMedGoogle Scholar
  • 88 Nelson R M, Cecconi O, Roberts W G. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation.  Blood . 1993;  82 3253-3258
    PubMedGoogle Scholar
  • 89 Norgard-Sumnicht K E, Varki N M, Varki A. Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells.  Science . 1993;  261 480-483
    PubMedGoogle Scholar
  • 90 Koenig A, Norgard-Sumnicht K E, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins-implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.  J Clin Invest . 1998;  101 877-889
    CrossrefPubMedGoogle Scholar
  • 91 Ma Y Q, Geng J G. Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375 cells to P-selectin under flow.  J Immunol . 2000;  165 558-565
    PubMedGoogle Scholar
  • 92 Xie X, Rivier A S, Zakrzewicz A. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides-studies with carboxyl-reduced and sulfated heparin and with trestatin A sulfate.  J Biol Chem . 2000;  275 30718-30711
    PubMedGoogle Scholar
  • 93 Varki A, Varki N M. P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic potential.  Braz J Med Biol Res . 2001;  34 711-717
    PubMedGoogle Scholar
  • 94 Fidler I J, Schroit A J. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self.  Biochim Biophys Acta . 1988;  948 151-173
    PubMedGoogle Scholar
  • 95 Sawada R, Tsuboi S, Fukuda M. Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials.  J Biol Chem . 1994;  269 1425-1431
    PubMedGoogle Scholar
  • 96 Izumi Y, Taniuchi Y, Tsuji T. Characterization of human colon carcinoma variant cells selected for sialyl Lex carbohydrate antigen: liver colonization and adhesion to vascular endothelial cells.  Exp Cell Res . 1995;  216 215-221
    CrossrefPubMedGoogle Scholar
  • 97 Mannori G, Santoro D, Carter L. Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin.  Am J Pathol . 1997;  151 233-243
    PubMedGoogle Scholar
  • 98 Ohyama C, Tsuboi S, Fukuda M. Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells.  EMBO J . 1999;  18 1516-1525
    CrossrefPubMedGoogle Scholar
  • 99 Leppänen A, Mehta P, Ouyang Y B. A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin.  J Biol Chem . 1999;  274 24838-24848
    CrossrefPubMedGoogle Scholar
  • 100 Yang J, Hirata T, Croce K. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration.  J Exp Med . 1999;  190 1769-1782
    CrossrefPubMedGoogle Scholar
  • 101 Handa K, White T, Ito K. P-Selectin-dependent adhesion of human cancer cells: requirement for co-expression of a `PSGL-1-like' core protein and the glycosylation process for sialosyl-Lex or sialosyl-Lea .  Int J Oncol . 1995;  6 773-781
    PubMedGoogle Scholar
  • 102 Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator.  Trends Cell Biol . 2001;  11 75-82
    CrossrefPubMedGoogle Scholar
  • 103 Hirsh J, Warkentin T E, Shaughnessy S G. Heparin and low-molecular-weight heparin-mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.  Chest . 2001;  119(Suppl) 64S-94S
    CrossrefPubMedGoogle Scholar
  • 104 Agnelli G. Pharmacological activities of heparin chains: should our past knowledge be revised?.  Haemostasis . 1996;  26(Suppl 2) 2-9
    PubMedGoogle Scholar
  • 105 Salmivirta M, Lidholt K, Lindahl U. Heparan sulfate: a piece of information.  FASEB J . 1996;  10 1270-1279
    PubMedGoogle Scholar
  • 106 Miao H Q, Elkin M, Aingorn E. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides.  Int J Cancer . 1999;  83 424-431
    CrossrefPubMedGoogle Scholar
  • 107 Parish C R, Freeman C, Brown K J, Francis D J, Cowden W B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.  Cancer Res . 1999;  59 3433-3441
    PubMedGoogle Scholar
  • 108 Folkman J, Weisz P B, Joullié M M, Li W W, Ewing W R. Control of angiogenesis with synthetic heparin substitutes.  Science . 1989;  243 1490-1493
    PubMedGoogle Scholar
  • 109 Fareed J, Hoppensteadt D A, Bick R L. An update on heparins at the beginning of the new millennium.  Semin Thromb Hemost . 2000;  26(Suppl 1) 5-21
    PubMedGoogle Scholar
  • 110 Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis?.  Thromb Res . 2000;  100 V113-V120
    CrossrefPubMedGoogle Scholar
  • 111 Van der Heijden F J, Prins M H, Büller H R. Low-molecular-weight heparins: are they interchangeable?.  Haemostasis . 2000;  30(Suppl 2) 148-157
    CrossrefPubMedGoogle Scholar
  • 112 Huang J N, Shimamura A. Low-molecular-weight heparins.  Hematol Oncol Clin North Am . 1998;  12 1251-1281
    PubMedGoogle Scholar
  • 113 Valentine K A, Hull R D, Pineo G F. Low-molecular-weight heparin therapy and mortality.  Semin Thromb Hemost . 1997;  23 173-178
    PubMedGoogle Scholar
  • 114 Kakkar A K, Williamson R CN. Prevention of venous thromboembolism in cancer patients.  Semin Thromb Hemost . 1999;  25 239-243
    Article in Thieme ConnectPubMedGoogle Scholar
  • 115 Brown D C, Purushotham A D, Birnie G D, George W D. Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction.  Surgery . 1995;  117 95-101
    PubMedGoogle Scholar
  • 116 Al-Mehdi A B, Tozawa K, Fisher A B. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis.  Nature Med . 2000;  6 100-102
    PubMedGoogle Scholar
      >